Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
These abstracts report on the company's three lead drug candidates, including olverembatinib
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Subscribe To Our Newsletter & Stay Updated
